Mark Mintun
Overview
Explore the profile of Mark Mintun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1803
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zimmer J, Ardayfio P, Wang H, Khanna R, Evans C, Lu M, et al.
JAMA Neurol
. 2025 Mar;
PMID: 40063015
Importance: Amyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies....
2.
Cummings J, Gold M, Mintun M, Irizarry M, von Eschenbach A, Hendrix S, et al.
J Prev Alzheimers Dis
. 2025 Jan;
12(1):100001.
PMID: 39800453
There is growing consensus in the Alzheimer's community that combination therapy will be needed to maximize therapeutic benefits through the course of the disease. However, combination therapy raises complex questions...
3.
Fleisher A, Munsie L, Perahia D, Andersen S, Higgins I, Hauck P, et al.
Neurology
. 2024 Feb;
102(5):e208061.
PMID: 38386949
Background And Objectives: Zagotenemab (LY3303560), a monoclonal antibody that preferentially targets misfolded, extracellular, aggregated tau, was assessed in the PERISCOPE-ALZ phase 2 study to determine its ability to slow cognitive...
4.
Sims J, Zimmer J, Evans C, Lu M, Ardayfio P, Sparks J, et al.
JAMA
. 2023 Jul;
330(6):512-527.
PMID: 37459141
Importance: There are limited efficacious treatments for Alzheimer disease. Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. Design, Setting, And Participants:...
5.
Charil A, Shcherbinin S, Southekal S, Devous M, Mintun M, Murray M, et al.
J Alzheimers Dis
. 2019 Sep;
71(3):1037-1048.
PMID: 31476153
At autopsy, individuals with Alzheimer's disease (AD) exhibit heterogeneity in the distribution of neurofibrillary tangles in neocortical and hippocampal regions. Subtypes of AD, defined using an algorithm based on the...
6.
Honig L, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al.
N Engl J Med
. 2018 Jan;
378(4):321-330.
PMID: 29365294
Background: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides...
7.
Tosun D, Landau S, Aisen P, Petersen R, Mintun M, Jagust W, et al.
Brain
. 2017 Mar;
140(5):1499-1512.
PMID: 28334939
See Vandenberghe and Schaeverbeke (doi:10.1093/awx065) for a scientific commentary on this article. A long-term goal of our field is to determine the sequence of pathological events, which ultimately lead to...
8.
Barret O, Alagille D, Sanabria S, Comley R, Weimer R, Borroni E, et al.
J Nucl Med
. 2016 Dec;
58(7):1124-1131.
PMID: 27908967
F-AV-1451 is currently the most widely used of several experimental tau PET tracers. The objective of this study was to evaluate F-AV-1451 binding with full kinetic analysis using a metabolite-corrected...
9.
Coric V, Salloway S, van Dyck C, Dubois B, Andreasen N, Brody M, et al.
JAMA Neurol
. 2015 Sep;
72(11):1324-33.
PMID: 26414022
Importance: Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the...
10.
Landau S, Fero A, Baker S, Koeppe R, Mintun M, Chen K, et al.
J Nucl Med
. 2015 Mar;
56(4):567-74.
PMID: 25745095
Unlabelled: The accurate measurement of β-amyloid (Aβ) change using amyloid PET imaging is important for Alzheimer disease research and clinical trials but poses several unique challenges. In particular, reference region...